Moderna surprises the Street by predicting a bigger-than-expected sales drop
Shares of Moderna tumbled in early trading Monday after the vaccine maker predicted a steeper-than-expected sales drop in the ...
Moderna stock drops on lower 2025 guidance, more cost cuts
Moderna Inc. entered the new year on the heels of a worsening stock performance in 2024. The Cambridge drugmaker’s stock ...
Why Moderna Stock Just Crashed 21%
Moderna 's ( MRNA -20.49%) sales are slowing down, and Moderna stock is going down -- a lot. The coronavirus vaccine maker's ...
Moderna 2025 Revenue Guidance Below Wall Street’s Estimates
The biotech company said it expects between $1.5 billion and $2.5 billion in revenue this year, below Wall Street ...
Watch These Moderna Price Levels as Stock Plummets After Slashing 2025 Revenue Outlook
Moderna shares will likely remain under scrutiny after plunging nearly 17% Monday as the embattled drug maker slashed its ...
Moderna’s Financial Outlook Dims Amid Vaccine Challenges and Revised Sales Forecasts, Warrants Sell Rating
In a report released today, Tim Anderson from Bank of America Securities maintained a Sell rating on Moderna (MRNA – Research Report), with a ...
FiercePharma22h
JPM25: Moderna slashes guidance, plots $1B in cost cuts this year amid lackluster vaccine sales
Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...
Biogen, Moderna, and other Mass. biotech firms making headlines amid JPMorgan Healthcare Conference
“In the end," Vrabel said. "It was clear to me, and to my family, and my soul, that this was the place that I wanted to be.” ...